The increase in patient awareness and the longer life expectancies are driving the growth of the Chinese diabetes market. There is potentially great opportunity for multinational pharmaceutical…
The availability of novel disease-modifying therapies (DMTs), such as the oral DMTs Novartis’s Gilenya (fingolimod), Genzyme’s Aubagio (teriflunomide), and Biogen Idec’s Tecfidera (dimethyl…
For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI), serotonin/norepinephrine reuptake inhibitor (…
Three new premium-priced therapies–Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare)–have recently been approved in Europe for prostate cancer…
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Last Updated 3 November 2014 Approximately 1.2 million people in the major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are…
This report leverages physician insights as well as patient chart data to provide the most up-to-date information about chronic kidney disease non-dialysis (CKD-ND) patient care in the US,…
Last Updated 28 October 2014 Psoriasis is a skin disorder that, depending on its severity and location on the body, can have a major impact on patients’ quality of life. It is generally…
Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (…
Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and…
Last Updated 24 October 2014 The prostate cancer market has witnessed considerable changes over the last four years with the launch of five therapies for metastatic castrate-resistant prostate…
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
While Genentech’s Lucentis continues to be the gold-standard treatment for wet age-related macular degeneration (AMD) in the United States, off-label use of Genentech’s Avastin (often…
